In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...

Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Understand the difference between targeted therapy, chemotherapy, and immunotherapy in lung cancer — and why starting the wrong treatment first can be harmful for patients with targetable mutations.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, ...

Neuroendocrine neoplasms are a heterogeneous group of malignancies ranging from indolent well-differentiated neuroendocrine tumors (NETs) to aggressive poorly differentiated neuroendocrine carcinomas ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Justyna Kelly as Chief Technology Officer (CTO) ...

Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief Scientific Officer, further building AdvanCell’s U.S. based leadership team Simon Puttick, PhD, ...

LJUBLJANA, Slovenia--(BUSINESS WIRE)--Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed ...

Though alpha radioactivity was discovered more than 125 years ago, where the particle comes from is still a mystery, especially in nuclei that have large numbers of protons and neutrons. "Alpha decay ...

Stanford Medicine Cancer Center delivers the world’s first patient treatment using an ultra-compact proton therapy system installed in an existing conventional radiation therapy vault LITTLETON, Mass.

About one-third of people with newly diagnosed acute myeloid leukemia (AML) have a mutation in the FLT3 gene, which instructs a protein that helps white blood cells grow. FLT3 inhibitors like ...